Precigen Reports Strong Q1 Revenue Growth from Papzimeos, Significantly Reduces Net Loss
PGEN has more than doubled off its 52-week low of $1.26.
Summary
Precigen, Inc. announced strong Q1 2026 financial results, with significant revenue growth from its new drug Papzimeos and a reduced net loss, but also reported increased cash burn and new 10b5-1 selling plans from top executives.
Key Events · Earnings and Guidance · PGEN
-
Strong Q1 2026 Revenue Growth
Total revenues increased to $23.252 million in Q1 2026 from $1.341 million in Q1 2025, primarily driven by $21.591 million in product revenue from Papzimeos, which had no sales in the prior-year period.
-
Significant Reduction in Net Loss
Net loss decreased substantially to $7.929 million in Q1 2026 from $54.153 million in Q1 2025, reflecting improved financial performance as the company transitions to commercialization.
-
Increased Operating Cash Burn
Net cash used in operating activities increased to $43.827 million in Q1 2026, up from $16.325 million in Q1 2025, indicating higher operational expenditures despite revenue growth.
-
C-Suite Executives Adopt 10b5-1 Selling Plans
The CEO, CFO, COO, and CCO adopted or amended Rule 10b5-1 trading arrangements to sell an aggregate of 1,013,861 shares of common stock, valued at approximately $4.2 million, starting June 29, 2026.
Analysis · PGEN · Life Sciences
Precigen, Inc. reported a substantial increase in Q1 2026 revenue, primarily driven by its newly approved drug Papzimeos, leading to a significant reduction in net loss. This marks a critical transition to a commercial-stage company. However, the company experienced a notable increase in operating cash burn, and several C-suite executives adopted 10b5-1 selling plans, indicating a mixed outlook despite the commercial success.
At the time of this filing, PGEN was trading at $4.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $1.26 to $5.47. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.